• English
    • Deutsch
  • English 
    • English
    • Deutsch
  • Login
View Item 
  •   Home
  • Universität Ulm / Medizin
  • Publikationen
  • View Item
  •   Home
  • Universität Ulm / Medizin
  • Publikationen
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Measuring therapeutic efficacy in patients with Alzheimer’s disease: role of instruments

Thumbnail
DEM326214.pdf (260.2Kb)

peer-reviewed

Erstveröffentlichung
2011-04-07
Authors
Riepe, Matthias W.
Janetzky, Wolfgang
Lemming, Ole M.
Wissenschaftlicher Artikel


Published in
Dementia and Geriatric Cognitive Disorders ; 31 (2011), 3. - S. 233-238. - ISSN 1420-8008. - eISSN 1421-9824
Link to original publication
https://dx.doi.org/10.1159/000326214
Institutions
UKU. Klinik für Psychiatrie und Psychotherapie II
External cooperations
Lundbeck GmbH Pharmaunternehmen
Document version
published version (publisher's PDF)
Abstract
Background/Aims: Global cognitive scales and meta-analyses thereof are used to appraise therapeutic efficacy over a broad range of disease severity. Clinically, however, different aspects of cognition change in different stages of disease. Methods: Calculation of effect sizes for single cognitive functions on treatment as assessed by the Alzheimer’s Disease Assessment Scale (ADAS-cog), the Mini-Mental-Status Examination (MMSE), and the Severe Impairment Battery (SIB). In these scales, subdomains of ‘cognition’, e.g. memory and language, are represented in different proportions. To exemplify the analysis of ‘cognition’, we used original data of previously published clinical studies with memantine. Results: Depending on dementia severity and on the scale used, the effect size for memory varies between –0.44 and +0.34 and for language between –0.40 and +0.26. Conclusion: Beyond interstudy variance, effect sizes for treatment with antidementia drugs are subject to disease stage, instruments used, and interaction thereof. Therefore, clinical interpretation is necessary to appraise therapeutic efficacy in clinical studies and meta-analyses thereof when patients with different severity are included or different instruments are used. Alternatively, severity-adapted endpoints should be used for appraisal and meta-analysis of therapeutic efficacy. © In Copyright http://rightsstatements.org/vocab/InC/1.0/
Subject headings
[GND]: Alzheimerkrankheit | Therapie | Kognition | Metaanalyse
[MeSH]: Alzheimer disease; Therapy | Cognition | Meta-analysis
[Free subject headings]: Effect size
Rights notice
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
 
This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
License
In Copyright
http://rightsstatements.org/vocab/InC/1.0/

Metadata
Show full item record

DOI & citation

Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-40131

Riepe, Matthias W.; Janetzky, Wolfgang; Lemming, Ole M. (2021): Measuring therapeutic efficacy in patients with Alzheimer’s disease: role of instruments. Open Access Repositorium der Universität Ulm und Technischen Hochschule Ulm. http://dx.doi.org/10.18725/OPARU-40131
Citation formatter >



Policy | kiz service OPARU | Contact Us
Impressum | Privacy statement
 

 

Advanced Search

Browse

All of OPARUCommunities & CollectionsPersonsInstitutionsPublication typesUlm SerialsDewey Decimal ClassesEU projects UlmDFG projects UlmOther projects Ulm

My Account

LoginRegister

Statistics

View Usage Statistics

Policy | kiz service OPARU | Contact Us
Impressum | Privacy statement